|
|
|
|
|
|
|
|
|
16.12.25 - 15:09
|
CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer (Business Wire)
|
|
|
PITTSBURGH--(BUSINESS WIRE)--#CytoAgents--CytoAgents, Inc. a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation, announced today the appointment of Dr. Johannes Wolff, MD, PhD, as Chief Medical Officer (CMO) and Michael D. Howell, PhD, as Chief Scientific Officer (CSO).
Dr. Johannes Wolff, MD, PhD, Chief Medical Officer
Dr. Wolff brings over three decades of distinguished leadership in academic medicine and the pharmaceutical industry, with deep expertise in clinical trial strategy, drug development, and medical affairs. Originally trained as a pediatric hematologist-oncologist, Dr. Wolff has held senior roles in both academic and industry settings, including Vice President of Clinical Development at Replimune, Senior Medical Director at AbbVie and Novartis, and department chair positions at leading institutions such as Cleveland Clinic and Tufts Medical Center. He has led successful Investigational New Drug applications, pivo...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.12.25 - 12:00
|
AbbVie: Top-Pick für Pharma-Anleger? (Sharedeals)
|
|
|
Die Aktie von AbbVie hat sich 2025 zu einem der auffälligsten Lichtblicke im sonst schwächelnden Pharmasektor entwickelt. Während viele Gesundheitswerte unter dem Druck neuer Technologie-Hypes litten, avancierte AbbVie zu einem überraschenden Outperformer und setzte ein klares Signal an den Markt. Während viele große Pharmakonzerne im anhaltenden KI-Boom an Aufmerksamkeit verloren, legte AbbVie einen bemerkenswerten Kursanstieg […]
The post AbbVie: Top-Pick für Pharma-Anleger? first appeared on sharedeals.de....
|
|
|
|
|
09.12.25 - 18:03
|
Medincell Publishes its Consolidated Half-Year Financial Results (Business Wire)
|
|
|
(April 1st, 2025 - September 30, 2025)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
Christophe Douat, CEO of Medincell (Paris:MEDCL): “We are pleased with the company's growth and momentum. We have entered the most transformative years in Medincell's history. UZEDY delivers strong performance and the expected launch of olanzapine LAI next year is poised to be a major catalyst for Medincell's growth. We keep advancing the third engine of our Shift to Growth strategy, with our first program in partnership with AbbVie leading the way, while further expanding and diversifying our pipeline and collaborations with leading pharmaceutical partners.”
Stéphane Postic, CFO of Medincell: “Revenues are growing and are expected to accelerate in the coming years with Olanzapine LAI. We have refined our investment plan to allocate resources strategically, with discipline and ambition. This approach is designed to create sustainable value and position Medincell for long-term success.”
Consolidated fi...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
